Calcitonin Injection Sector Forecast Shows Robust Momentum, Climbing to $1.07 Billion With 8.1% CAGR

Uncover key drivers, emerging technologies, and competitive movements shaping the calcitonin injection market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Calcitonin Injection Market between 2026 and 2030?

The calcitonin injection market has observed significant expansion in recent years. It is anticipated to expand from $0.73 billion in 2025 to $0.79 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.4%. The factors contributing to this growth in the past period include the widespread prevalence of osteoporosis, the adoption of hospital injectable therapies, the implementation of fracture management protocols, the incidence of calcium metabolism disorders, and an increasing aging population.

The calcitonin injection market is expected to experience strong expansion in the next few years, with its size projected to grow to $1.07 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. This growth during the forecast period can be attributed to factors such as geriatric population growth, increasing demand for injectable therapy, enhanced bone disease awareness, ongoing synthetic peptide development, and the expansion of specialty care. Major trends anticipated in the forecast period include the continued use of calcitonin in osteoporosis management, the rise of injectable bone therapies, an expansion of hypercalcemia treatment, a heightened focus on geriatric bone health, and a notable shift toward synthetic calcitonin.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24490&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Calcitonin Injection Market?

The rising occurrence of osteoporosis is projected to boost the expansion of the calcitonin injection market in the coming years. Osteoporosis is a medical condition marked by reduced bone density and a higher susceptibility to fractures, predominantly impacting older individuals, particularly women after menopause. This rise in osteoporosis cases stems from the aging global population, as extended lifespans naturally result in bone density loss and an elevated risk of developing the condition. Calcitonin injection supports the treatment of osteoporosis by moderating calcium levels and impeding bone deterioration, thus proving instrumental in sustaining bone density. It delivers a focused therapeutic approach via simple-to-administer injections, which enhances patient adherence and diminishes the likelihood of fractures. For instance, in August 2024, according to Healthy Bones Australia, an Australia-based nonprofit organization focused on osteoporosis prevention and bone health, an estimated 6.2 million Australians aged 50 years and older, representing about 67 percent of this age group, were living with poor bone health in 2023, and around 23 percent of these individuals were affected by osteoporosis. Consequently, the growing incidence of osteoporosis is stimulating the development of the calcitonin injection market.

How Is The Calcitonin Injection Market Organized Into Various Segments?

The calcitonin injection market covered in this report is segmented –

1) By Type Of Calcitonin: Salmon Calcitonin, Human Calcitonin, Synthetic Calcitonin

2) By Route Of Administration: Intravenous (IV) Injection, Subcutaneous Injection, Intramuscular Injection

3) By Distribution Channel: Direct Sales, Online Pharmacy, Retail Pharmacy, Healthcare Institutions

4) By Therapeutic Application: Osteoporosis Treatment, Pagets Disease Management, Hypercalcemia Control, Bone Metastases Therapy

5) By End-User: Hospitals, Specialty Clinics, Geriatric Care Facilities, Home Healthcare

Subsegments:

1) By Salmon Calcitonin, Synthetic Salmon Calcitonin, Recombinant Salmon Calcitonin

2) By Human Calcitonin, Recombinant Human Calcitonin, Synthetic Human Calcitonin

3) By Synthetic Calcitonin, Peptide-Based Synthetic Calcitonin, Analog Synthetic Calcitonin

How Are New Market Trends Shaping The Landscape Of The Calcitonin Injection Market?

Leading companies in the calcitonin injection market are concentrating on creating advanced products, such as USP synthetic injections, with the aim of boosting treatment effectiveness and enhancing patient results. USP Synthetic Injections are injectable drugs that comprise active ingredients produced synthetically, adhering to the stringent quality, purity, strength, and identity criteria established by the United States Pharmacopeia (USP). These injections are produced under controlled conditions to guarantee their safety and efficacy for therapeutic application. For instance, in February 2025, the German pharmaceutical firm Fresenius Kabi introduced calcitonin salmon injection, a USP synthetic product, for managing symptomatic Paget’s disease of the bone and hypercalcemia. This sterile solution, designed for intramuscular or subcutaneous administration, is offered in a concentration of 200 USP units per mL and comes in a 2 mL multi-dose vial containing 400 USP units. It requires refrigeration between 2°C and 8°C. Functioning as a calcium regulator, this injectable medicine is prescribed for symptomatic Paget’s disease of bone when other treatments are not suitable, for hypercalcemia, and for postmenopausal osteoporosis when alternative options are inappropriate.

Who Are The Major Companies Operating In The Calcitonin Injection Market?

Major companies operating in the calcitonin injection market are Pfizer Inc., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Lupin Limited, Aurobindo Pharma Limited, Zydus Lifesciences Limited, Glenmark Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Alkem Laboratories Limited, Intas Pharmaceuticals Limited, Emcure Pharmaceuticals Limited, Wockhardt Limited, Accord Healthcare Ltd., Sandoz International GmbH, Amneal Pharmaceuticals LLC, Apotex Inc., Mylan N.V., Cadila Pharmaceuticals Limited, Macleods Pharmaceuticals Ltd., Bharat Parenterals Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/calcitonin-injection-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Calcitonin Injection Market?

North America was the largest region in the calcitonin injection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin injection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Calcitonin Injection Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24490&type=smp

Browse Through More Reports Similar to the Global Calcitonin Injection Market 2026, By The Business Research Company

Companion Animal Pharmaceuticals Market Report 2026

https://www.thebusinessresearchcompany.com/report/companion-animal-pharmaceuticals-global-market-report

Pharmaceutical Excipient Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-excipient-global-market-report

Pharmaceutical Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795